Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Cigarette smoking history-Current or ex-smokers (defined as stopped smoking for at least three months prior to the study visit)
Established history of COPD as diagnosed by a physician
Regular use (prescribed for use every day) of only one long-acting bronchodilator greater than or equal to one month before the study visit
Ability to read, comprehend, and record information in the English language
You may not be if
Currently active asthma (receiving asthma therapy and or having asthma symptoms)
Use of ipratropium/albuterol combination products greater than three times per day, use of inhaled corticosteroids, use of inhaled corticosteroid/long-acting beta-agonist combinations, theophylline preparations, or oral beta agonists within 3 months prior to the study visit
Previous lung surgery
Other respiratory disorders other than COPD
Current alcohol, illegal drug, or solvent abuse
Females with a positive urine pregnancy test at the study visit
Clareo Health | Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
